1. Home
  2. ENOV vs KYMR Comparison

ENOV vs KYMR Comparison

Compare ENOV & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENOV
  • KYMR
  • Stock Information
  • Founded
  • ENOV 1995
  • KYMR 2015
  • Country
  • ENOV United States
  • KYMR United States
  • Employees
  • ENOV N/A
  • KYMR N/A
  • Industry
  • ENOV Fluid Controls
  • KYMR Medicinal Chemicals and Botanical Products
  • Sector
  • ENOV Industrials
  • KYMR Health Care
  • Exchange
  • ENOV Nasdaq
  • KYMR Nasdaq
  • Market Cap
  • ENOV 2.1B
  • KYMR 2.2B
  • IPO Year
  • ENOV 2008
  • KYMR 2020
  • Fundamental
  • Price
  • ENOV $36.95
  • KYMR $26.42
  • Analyst Decision
  • ENOV Buy
  • KYMR Buy
  • Analyst Count
  • ENOV 4
  • KYMR 13
  • Target Price
  • ENOV $58.50
  • KYMR $56.69
  • AVG Volume (30 Days)
  • ENOV 849.1K
  • KYMR 627.3K
  • Earning Date
  • ENOV 05-01-2025
  • KYMR 05-01-2025
  • Dividend Yield
  • ENOV N/A
  • KYMR N/A
  • EPS Growth
  • ENOV N/A
  • KYMR N/A
  • EPS
  • ENOV N/A
  • KYMR N/A
  • Revenue
  • ENOV $2,107,623,000.00
  • KYMR $47,072,000.00
  • Revenue This Year
  • ENOV $7.09
  • KYMR $44.93
  • Revenue Next Year
  • ENOV $6.38
  • KYMR N/A
  • P/E Ratio
  • ENOV N/A
  • KYMR N/A
  • Revenue Growth
  • ENOV 23.45
  • KYMR N/A
  • 52 Week Low
  • ENOV $34.44
  • KYMR $24.36
  • 52 Week High
  • ENOV $62.79
  • KYMR $53.27
  • Technical
  • Relative Strength Index (RSI)
  • ENOV 38.61
  • KYMR 25.51
  • Support Level
  • ENOV $36.43
  • KYMR $24.36
  • Resistance Level
  • ENOV $38.56
  • KYMR $35.28
  • Average True Range (ATR)
  • ENOV 1.44
  • KYMR 1.74
  • MACD
  • ENOV 0.08
  • KYMR -0.68
  • Stochastic Oscillator
  • ENOV 40.10
  • KYMR 9.84

About ENOV Enovis Corporation

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Share on Social Networks: